IID572  is a potent and broad spectrum β-lactamase
inhibitor that does not inhibit PBP-2 and lacks measurable
intrinsic antibacterial activity. This may remove potential
development and therapeutic liabilities attributed to selective
PBP-2 inhibition. It effectively protects piperacillin
against degradation by serine β-lactamase-expressing drugresistant Enterobacteriaceae and other organisms, restoring
activity against the majority of TZP-resistant strains tested. The
pharmacokinetic parameters for IID572 were evaluated in rodents
and dog and found to be similar to avibactam, except for it
having a longer half-life, especially in dog. PIP/12 but not TZP
showed efficacy against aKPC-expressingstrain of K. pneumoniae
in the murine thigh infection model.